Brown Advisory Inc. Has $44.72 Million Stock Holdings in SiBone (NASDAQ:SIBN)

Brown Advisory Inc. reduced its position in SiBone (NASDAQ:SIBN - Free Report) by 12.4% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 3,187,398 shares of the company's stock after selling 453,047 shares during the period. Brown Advisory Inc. owned 7.51% of SiBone worth $44,719,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtus Fund Advisers LLC acquired a new stake in SiBone in the fourth quarter worth $40,000. GAMMA Investing LLC increased its holdings in shares of SiBone by 20,352.6% in the first quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after acquiring an additional 3,867 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of SiBone during the fourth quarter worth about $97,000. Johnson Investment Counsel Inc. bought a new position in shares of SiBone during the 1st quarter valued at about $148,000. Finally, Proficio Capital Partners LLC acquired a new position in shares of SiBone in the 4th quarter valued at approximately $155,000. 98.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have commented on SIBN. Truist Financial raised their target price on shares of SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of SiBone in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price objective on shares of SiBone in a research report on Tuesday, May 6th.

Insider Activity

In other news, SVP Michael A. Pisetsky sold 3,127 shares of the firm's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $18.29, for a total value of $57,192.83. Following the completion of the transaction, the senior vice president owned 261,681 shares in the company, valued at $4,786,145.49. This trade represents a 1.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Anthony J. Recupero sold 3,310 shares of the stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $18.27, for a total value of $60,473.70. Following the transaction, the insider directly owned 279,121 shares of the company's stock, valued at $5,099,540.67. This trade represents a 1.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 101,702 shares of company stock worth $1,866,404. 3.90% of the stock is currently owned by company insiders.

SiBone Stock Up 1.5%

SiBone stock traded up $0.27 during midday trading on Wednesday, reaching $18.44. The stock had a trading volume of 232,859 shares, compared to its average volume of 392,895. The stock has a market capitalization of $785.91 million, a P/E ratio of -28.81 and a beta of 0.93. The firm's fifty day simple moving average is $17.97 and its 200-day simple moving average is $16.24. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.26 and a current ratio of 8.53. SiBone has a 1-year low of $11.70 and a 1-year high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. The company had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. SiBone had a negative net margin of 15.03% and a negative return on equity of 16.00%. As a group, analysts expect that SiBone will post -0.78 EPS for the current fiscal year.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.